Chugai beëindigt onderzoek naar ALK-inhibitor Alecensa wegens vroeg resultaat
TOKYO–(BUSINESS WIRE)– Chugai Pharmaceutical Co., Ltd. heeft bekendgemaakt dat een onafhankelijke databeoordelaar heeft aanbevolen zijn onderzoek J-ALEX voortijdig te beëindigen, omdat het onderzoek zijn primaire eindpunt bij een tussentijdse analyse heeft behaald. J-ALEX is een fase 3-onderzoek naar ALK-fusiegenpositieve, niet-kleincellige longkanker. Het onderzoek wees uit dat patiënten na een behandeling met Alecensa significant langer leefden zonder verergering van de ziekte in vergelijking met een behandeling met crizotinib.
J-ALEX is een gerandomiseerd open-labelonderzoek dat de effectiviteit en veiligheid van Alecensa en crizotinib vergelijkt. J-ALEX had 207 deelnemende patiënten met gevorderde of teruggekeerde ALK-fusiegenpositieve, niet-kleincellige longkanker die nog geen chemokuur of slechts een chemokuur hadden doorlopen. De deelnemers zijn gelijk onderverdeeld in de groep met Alecensa en crizotinib.
Chugai’s ALK Inhibitor “Alecensa®” Trial Stopped Early for Benefit
TOKYO–(BUSINESS WIRE)– Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received a recommendation by an independent data monitoring committee (IDMC) that the J-ALEX Study, a phase III study targeting ALK fusion gene positive non-small cell lung cancer (NSCLC) being conducted in Japan, should be stopped early as the study met its primary endpoint at a pre-planned interim analysis. The study showed that patients lived significantly longer without disease worsening (progression-free survival, PFS) when treated with Alecensa® compared to crizotinib.
The J-ALEX study is an open-label, randomized phase III study that compares the efficacy and safety between Alecensa and crizotinib. The J-ALEX study enrolled 207 patients with ALKfusion gene positive advanced or recurrent NSCLC who either had not undergone chemotherapy or had undergone one chemotherapy regimen. The subjects were allocated to the Alecensa group or the crizotinib group in a one to one ratio.
Chugai carried out a prospectively defined interim analysis of the J-ALEX study, and had an IDMC examine the results. Since the results showed that Alecensa significantly prolonged the PFS to a higher extent than anticipated, the committee decided to recommend an early discontinuation of the study, as described above. The safety issues of Alecensa have not been pointed out.
The data of the J-ALEX study will be presented at a future medical meeting, etc.
“The fact that the J-ALEX study received a recommendation by an IDMC to be stopped early due to positive effects is great news, and a blessing for the patients who are involved in the study.” said Chugai’s Director and Executive Vice President, Dr. Yutaka Tanaka. “We are extremely happy that these results can offer hope and encouragement to patients in need to be treated with Alecensa.”
As a top pharmaceutical company in the field of oncology in Japan, Chugai believes that early treatment using Alecensa in ALK fusion gene positive NSCLC is expected not only to prolong these patients’ PFS, but also enable them to face their disease with a positive hope for the future.
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2015 of Chugai totalled 498.8 billion yen and the operating income was 90.7 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160210005605/en/
Contacts
For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp